Image_3_Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment.TIFF
TNFα inhibitors have shaped the landscape of rheumatoid arthritis (RA) therapy with high clinical efficiency. However, their impact on T cell recall responses is not well-elucidated. We aimed to analyze the immune profiles of memory T cells in RA patients undergoing TNFα inhibitor Golimumab (GM) treatment. Frequencies of peripheral T cell subsets and cytokine expression profiles in memory T cells (TM) upon PMA/Ionomycine stimulation were determined by flow cytometry. Antigen-specific CD8 T cell immunity was analyzed through stimulating PBMCs with CMV-EBV-Flu (CEF) viral peptide pool and subsequent intracellular IFNγ staining. Both peripheral CD8 and CD4 T cells from GM treated patients had a shift pattern characterized by an enlarged effector TM and a reduced central TM cell population when compared to GM untreated group. An increase in the frequencies of TNFα+, IL-2+, and IL-17+ CD8 TM cells was observed whereas only TNFα+CD4 TM cells increased in GM treated patients. Moreover, GM treated patients contained more peripheral IFNγ-producing CD8 T cells specific to CEF viral peptides. Together, these results show a distinct T cell subset pattern and enhanced memory T cell immunity upon GM treatment, suggesting an immunoregulatory effect of TNF inhibitor Golimumab on peripheral memory T cell responses.
History
References
- https://doi.org//10.1056/NEJMra1004965
- https://doi.org//10.1038/nature01661
- https://doi.org//10.1146/annurev.immunol.14.1.397
- https://doi.org//10.1172/JCI36389
- https://doi.org//10.1186/ar2219
- https://doi.org//10.1007/s10875-011-9542-6
- https://doi.org//10.1016/j.smim.2004.08.013
- https://doi.org//10.1146/annurev.immunol.25.022106.141548
- https://doi.org//10.1038/44385
- https://doi.org//10.1038/ni.2035
- https://doi.org//10.1038/nri778
- https://doi.org//10.1007/BF00290522
- https://doi.org//10.4161/mabs.12304
- https://doi.org//10.1002/art.23383
- https://doi.org//10.1136/ard.2008.099010
- https://doi.org//10.1186/s13075-015-0516-6
- https://doi.org//10.1002/art.27348
- https://doi.org//10.1111/1756-185X.12723
- https://doi.org//10.1016/S0022-1759(01)00535-X
- https://doi.org//10.1186/ar619
- https://doi.org//10.1007/s10067-018-4011-8
- https://doi.org//10.1007/s00296-009-1179-x
- https://doi.org//10.1172/JCI117394
- https://doi.org//10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K
- https://doi.org//10.1093/rheumatology/keg171
- https://doi.org//10.1084/jem.20072707
- https://doi.org//10.1093/rheumatology/keq224
- https://doi.org//10.1002/art.1780390702
- https://doi.org//10.1136/ard.2003.008599
- https://doi.org//10.1093/rheumatology/keh437
- https://doi.org//10.1136/ard.62.6.561
- https://doi.org//10.1002/art.10847
- https://doi.org//10.1371/journal.pone.0030275
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity